bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
Company profile
Ticker
BHC
Exchange
Website
CEO
Thomas J. Appio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOVAIL Corp, BIOVAIL CORP INTERNATIONAL, BIOVAIL CORPORATION INTERNATIONAL, Valeant Pharmaceuticals International, Inc.
SEC CIK
Corporate docs
Subsidiaries
Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • AcuFocus Australia • Bausch Health Australia Pty Limited • Bausch & Lomb (Australia) Pty Limited • Bausch & Lomb Australia Holdings Pty Limited • Solta Medical Australia Pty Limited • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. • PharmaSwiss BH Društvo za trgovinu na veliko d.o.o. ...
BHC stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
15 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Bausch Health Announces First Quarter 2024 Results
2 May 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Bausch Health Announces Fourth-quarter and Full-year 2023 Results
22 Feb 24
8-K
Bausch Health Announces Board Refreshment
1 Feb 24
8-K/A
Financial Statements and Exhibits
13 Nov 23
Transcripts
BHC
Earnings call transcript
2024 Q1
2 May 24
BHC
Earnings call transcript
2023 Q4
22 Feb 24
BHC
Earnings call transcript
2023 Q3
2 Nov 23
BHC
Earnings call transcript
2023 Q2
3 Aug 23
BHC
Earnings call transcript
2023 Q2
3 Aug 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q3
3 Nov 22
Latest ownership filings
4
John Paulson
1 Apr 24
4
BRETT ICAHN
1 Apr 24
4
RUSSEL C ROBERTSON
1 Apr 24
4
AMY B WECHSLER
1 Apr 24
4
John S Barresi
4 Mar 24
4
THOMAS APPIO
4 Mar 24
4
Seana Carson
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
GOLDENTREE ASSET MANAGEMENT LP
13 Feb 24
SC 13D/A
ICAHN CARL C
7 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 755.00 mm | 755.00 mm | 755.00 mm | 755.00 mm | 755.00 mm | 755.00 mm |
Cash burn (monthly) | 69.00 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 114.02 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 640.98 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 9.3 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
57.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 170 |
Opened positions | 30 |
Closed positions | 84 |
Increased positions | 32 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 1.55 tn |
Total shares | 211.30 mm |
Total puts | 4.69 mm |
Total calls | 2.00 mm |
Total put/call ratio | 2.3 |
Largest owners | Shares | Value |
---|---|---|
Goldentree Asset Management | 27.64 mm | $221.71 bn |
Paulson & Co. | 26.44 mm | $212.04 bn |
BEN Franklin Resources | 15.80 mm | $126.73 bn |
National Bank of Canada | 15.65 mm | $121.75 bn |
VA Partners I | 14.43 mm | $135.65 mm |
NMR Nomura | 13.30 mm | $106.63 bn |
Healthcare Of Ontario Pension Plan Trust Fund | 13.00 mm | $104.26 bn |
Vanguard | 11.60 mm | $93.03 bn |
Hudson Bay Capital Management | 11.50 mm | $92.23 bn |
ING ING Groep | 7.50 mm | $60.15 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Paulson John | Common Shares, No Par Value | Grant | Acquire A | No | No | 10.61 | 5,890 | 62.49 k | 208,309 |
29 Mar 24 | Brett Icahn | Common Shares, No Par Value | Grant | Acquire A | No | No | 10.61 | 3,122 | 33.12 k | 108,500 |
29 Mar 24 | Robertson Russel C | Common Shares, No Par Value | Grant | Acquire A | No | No | 10.61 | 2,945 | 31.25 k | 225,279 |
29 Mar 24 | Wechsler Amy B | Common Shares, No Par Value | Grant | Acquire A | No | No | 10.61 | 647 | 6.86 k | 169,906 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 133 | 1.30 k | 499,905 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 1,561 | 15.30 k | 500,038 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 199 | 1.95 k | 501,599 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 4,420 | 43.32 k | 501,798 |
1 Mar 24 | Seana Carson | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 511 | 5.05 k | 506,218 |
1 Mar 24 | Seana Carson | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 16,973 | 167.86 k | 506,729 |
News
Bausch Health Announces Litigation Updates With Norwich Pharmaceuticals; Bausch Health And Norwich Have Filed Petitions For Panel Rehearing Or Rehearing En Banc
14 May 24
Why Bausch Health Companies Shares Are Falling After Q1 Results
2 May 24
Bausch Health Companies Q1 Sales $2.153 Miss $2.156B Estimate
2 May 24
RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $11
23 Apr 24
RBC Capital Reiterates Sector Perform on Bausch Health Companies, Maintains $12 Price Target
12 Apr 24
Press releases
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
17 May 24
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
15 May 24
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
14 May 24
Bausch Health Announces First Quarter 2024 Results
2 May 24
Bausch Health to Announce First-Quarter 2024 Results on May 2
11 Apr 24